This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. (EPEP)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Andrew Carr, St Vincent's Hospital
ClinicalTrials.gov Identifier:
NCT01715636
First received: October 18, 2012
Last updated: January 8, 2015
Last verified: January 2015
History of Changes
  Purpose

This study aims to describe the safety, tolerability and adherence to the coformulated anti-HIV drug tenofovir-emtricitabine-rilpivirine (eviplera) when given to men who have sex with men (MSM) following an actual or potential sexual exposure to HIV. This biomedical intervention is known as nonoccupational post-exposure prophylaxis (NPEP). Patients receive NPEP if they meet the criteria outlined in the 2007 National Australian NPEP Guidelines. Three or two anti-HIV drugs are administered for 28-days depending on the severity of the the assessed HIV acquisition risk. In this study eviplera would constitute 3-drug NPEP. Tenofovir-emtricitabine (truvada) a component of eviplera has been used in NPEP at SVH since 2006.

This is a multi site, prospective, open-label, non-randomised trial. Participants will be MSM who present at the various recruitment sites requesting NPEP. Initially, 50 eligible participants will be assigned to receive eviplera 25mg once daily taken with food for 28-days according to established Australian guidelines for the use of 3-drug NPEP. There will be 7 visits over a 12-week period. Follow-up post NPEP is for 8 weeks. If an interim analysis demonstrates acceptable safety, it is proposed to seek ethics approval to increase the samples size to 100 patients to gain more accurate information on regimen completion rate and on-drug adherence.

The primary study objectives are:

  1. To describe the safety of 28 days of NPEP using co-formulated FTC-RPV-TDF
  2. To describe the tolerability of 28 days of NPEP using FTC-RPV-TDF
  3. To describe on-drug adherence and regimen completion rates of 28 days of NPEP using FTC-RPV-TDF

Condition Intervention Phase
HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by Andrew Carr, St Vincent's Hospital:

Primary Outcome Measures:
  • To describe the safety of 28 days of nonoccupational post-exposure prophylaxis with Eviplera [ Time Frame: 28 days ]
    Objective AE and SAE data collection/grading utilising DAIDS data collection tool. Measurement of weight, electrolytes, urea, creatinine, eGFR, inorganic phosphate, calcium, liver function, glucose, amylase, lipase, creatine kinase, lactate


Secondary Outcome Measures:
  • To describe the tolerability of 28 days of nonoccupational post-exposure prophylaxis with Eviplera [ Time Frame: 28 days ]
    Subjective reporting of AEs with data collection/grading utilising DAIDS-AE


Other Outcome Measures:
  • on-drug adherence and regimen completion dates [ Time Frame: 28 days ]
Enrollment: 100
Study Start Date: December 2012
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Eviplera
Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg, one tablet, once daily, taken with food, for 28 days
 Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
Other Name: Eviplera

  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Man who has sex with men
  2. Age at least 18 years
  3. Eligible for 3-drug NPEP according to Australian guidelines for the use of 3-drug NPEP following an actual or potential sexual exposure to HIV or receptive anal intercourse with an unknown source
  4. Able to provide written, informed consent

  5. Able to commit to the study visits

    Exclusion Criteria:

  6. Non-sexual exposure
  7. Exposure occurring during sex between a man and a woman
  8. HIV infection diagnosed on day 1 serological testing including indeterminate serology consistent with possible primary HIV infection
  9. Use of any medication contraindicated with FTC-RPV-TDF
  10. Serum hepatic transaminase (alanine aminotransferase [ALT] greater than 5 times the upper limit of the normal range
  11. Serum estimated Glomerular Filtration Rate (eGFR) <60mL/min/ BSAc
  12. Current therapy for hepatitis B
  13. Day 1 serological evidence of chronic/active hepatitis B
  14. Previous NPEP containing FTC-RPV-TDF
  15. A patient with a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study, or interfere with the patient's participation for the full duration of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01715636

Locations
Australia, New South Wales
Sydney Sexual Heatlh Centre
Sydney, New South Wales, Australia, 2000
St Vincents Hospital
Sydney, New South Wales, Australia, 2010
Australia, Victoria
The Alfred Hospital
Melbourne, Victoria, Australia, 3004
Melbourne Sexual Health Centre
Melbourne, Victoria, Australia, 3053
Sponsors and Collaborators
Andrew Carr
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Andrew Carr, Professor, St Vincent's Hospital
ClinicalTrials.gov Identifier: NCT01715636     History of Changes
Other Study ID Numbers: 1.0 dated 28 May 2012
Carr (IN-AU-264-0119) ( Other Grant/Funding Number: Gilead Sciences Pty Ltd )
Study First Received: October 18, 2012
Last Updated: January 8, 2015

Additional relevant MeSH terms:
Tenofovir
Emtricitabine
Rilpivirine
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
 Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents

ClinicalTrials.gov processed this record on September 25, 2017